SPARX3

Conditions de participation

• Sexe:

  Female, Male

• Âges admissibles:

  40 to 80

Critères de participation

Inclusion Criteria:
1. A clear diagnosis of Parkinson's disease from a neurologist.
2. Hoehn and Yahr stage less than 3 (this is a rating a neurologist will determine).
3. Disease duration: less than 3 years since disease diagnosis
4. Age 40-80 years
5. Positive DaTscan™ SPECT by qualitative visual assessment.
6. (For women only) If not surgically sterile or postmenopausal, a negative pregnancy test will be required prior to receiving the DaTscan™ SPECT.
Exclusion Criteria:
1. Currently being treated with PD medications and/or expected to require treatment with medication for PD in the first 6 months of the study.
2. Use of any PD medication 60 days prior to the baseline visit and/or duration of previous use of medications for PD exceeds 30 days.
3. Use of neuroleptics/dopamine receptor blockers for more than 30 days in the year prior to baseline visit, or any use within 30 days of baseline visit
4. Any clinically significant medical condition, psychiatric condition (ie. depression), drug or alcohol abuse, assessment or laboratory abnormality that would, in the judgment of the investigator, interfere with the participant's ability to participate in the study.
5. Mild cognitive impairment.
6. Individuals participating in 120 minutes or more of moderate intensity exercise per week within the last 6 months will be excluded.
7. Use of certain medications within 90 days prior to the DaT neuroimaging screening evaluation.
8. Known allergy to iodinated products and/or known hypersensitivity to DaTscan™ SPECT.
9. Prior SPECT scan within 6 months of baseline scan.
10. (For women only) Actively breast-feeding an infant, and/or pregnant, or plan to become pregnant in the next 12 months.